



Épidémiologie des sarcomes en Belgique

Dr. Liesbet Van Eycken

12^{es} journées annuelles du GSF-GETO
Oud Sint-Jan Bruges, 22-24 juin 2016

A large, white version of the '10 years' logo is centered on a blue background with a bokeh effect of light circles. The '10' is stylized with a pie chart for the '0', and 'years' is in a lowercase sans-serif font.

Overview

•Introduction

•Descriptive epidemiology


- Incidence
- Age specific incidence
- TNM stage
- Survival

•Rarecarenet: HR study: soft tissue sarcoma, results for Belgium (extremities)

•Conclusion

Belgium 2013:


65.487 new cancer cases




~1300/year

* All malignant tumours (non-melanoma skin cancer included)

All Soft Tissue Sarcoma Incidence, 2004-2013




Belgium 2013, WHO classification of Tumours of Soft Tissue and Bone, 2013



- Stromal tumours (24.2%)
- Fibroblastic / Myofibroblastic tumours (11.4%)
- Myomatous neoplasms (10.8%)
- Mixed epithelial mesenchymal tumours (10.0%)
- Bone tumours (9.7%)
- Adipocytic tumours (8.3%)
- Undifferentiated/Unclassified sarcoma (8.3%)
- Vascular tumours (6.5%)
- Other specified sarcoma (3.9%)
- Nerve Sheath tumours (2.2%)
- Synovial neoplasms (2.0%)
- Phyllodes tumours (1.3%)
- Sarcoma of uncertain differentiation (1.3%)


Fibroblastic /myofibroblastic tumours

Belgium 2004-2013: N = 1,159




Fibroblastic / myofibroblastic tumours


Belgium 2004-2013: N = 1,159




Myomatous sarcoma Belgium 2004-2013: N = 1,530




Bone tumours, Belgium 2004-2013: N = 1,198




Bone tumours, Belgium 2004-2013: N = 1,198



Liposarcoma, Belgium 2004-2013: N = 1,024




Liposarcoma, Belgium 2004-2013: N = 1,024



Sarcoma subtypes, Belgium 2004-2013


TNM stage: **known** **unknown** **not applicable**




Sarcoma subtypes, Belgium 2004-2013




■ Stage I
 ■ Stage II
 ■ Stage III
 ■ Stage IV



Sarcoma subtypes, 5-year relative survival, Belgium 2004-2013



Liposarcoma, Belgium 2004-2013: N = 1,024



A cancer registry is a basic tool for cancer surveillance

- a. To serve public health by monitoring changes in cancer occurrence and prognosis (epidemiology) and evaluating mass interventions like **screening**
descriptive epidemiology: **incidence, survival and prevalence.**
- b. To serve **oncology** by studying access and variation in **quality of care and outcomes, including the patient perspective**, and cause-specific mortality. The methods of quality of care research also include **interpretation** of context and regular **feedback** to the clinicians involved.

Eurocourse FP7, JW Coebergh et al. 2012

Rarecarenet, soft tissue sarcoma (extremities)


10 years
Belgian Cancer Registry



Tumours diagnosed in 2009-2010, Belgium



High resolution study on Soft tissue sarcoma (limbs), n=280



Extended dataset: manual registration and merging of available data


Quality Indicators

1. Diagnostic management, biopsy
2. 2nd opinion pathology (expert)
3. Resection margins
4. Reoperation

Soft tissue sarcoma: Diagnostic management, histological verification



	N cases	biopsy	surgery without biopsy
Belgium	280	41%	59%



T	Freq.	%
T1	51	31.1
T1A	13	7.9
T1B	9	5.5
T2	44	26.8
T2A	9	5.5
T2B	15	9.2
missing or X	23	14.0
Total	164	100



Soft tissue sarcoma: volume and resection margins

Distribution of margin status after first/main surgery

hospital volume	R missing	Total
<=5	21	87
%	24.1	100
6 to 10	7	34
%	20.6	100
> 10	14	135
%	10.4	100
volume missing	21	24
%	87.5	100
Total	63	280
%	22.5	100

Soft tissue sarcoma: re-operation (22%)



Re-operation by hospital volume of main surgery

	N re-operation	N surgeries	%
<=5	32	87	37
6 to 10	7	34	21
>10	16	135	12
volume missing	3	5	60
Total	58	261	

Volume of the hospitals undertaking the re-operation

	Freq.	Percent
<=5	17	29.31
6 to 10	6	10.34
>10	34	58.62
volume missing	1	1.72
Total	58	100

- Thank you for your attention
- Thank you Kris Henau



All sarcoma



	Males	Females
Incidence 2013 (N)	560	632
Prevalence (5y)	1,912	2,208
Prevalence (10y)	3,218	3,825
Relative survival (5y)	67.6%	63.4%
Relative survival (10y)	62.2%	57.2%